ROYAL BANK OF CANADA - CHINA BIOLOGIC PRODS HLDGS I ownership

CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 90 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q4 2017. The put-call ratio across all filers is 15.82 and the average weighting 0.2%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$24,000
+2300.0%
202
+1920.0%
0.00%
Q4 2020$1,000
-95.0%
10
-95.0%
0.00%
Q2 2020$20,000
-16.7%
200
-8.7%
0.00%
Q1 2020$24,000
-4.0%
2190.0%0.00%
Q4 2019$25,0000.0%2190.0%0.00%
Q3 2019$25,000
+19.0%
2190.0%0.00%
Q2 2019$21,000
+90.9%
219
+56.4%
0.00%
Q1 2018$11,000
+1000.0%
140
+2233.3%
0.00%
Q3 2017$1,00060.00%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q4 2017
NameSharesValueWeighting ↓
Maso Capital Partners Ltd 627,111$74,068,00020.20%
Athos Capital Ltd 362,909$42,863,00011.81%
PSquared Asset Management AG 205,000$24,213,0003.85%
York Capital Management Global Advisors, LLC 302,675$35,749,0003.52%
HHLR ADVISORS, LTD. 2,962,076$349,851,0002.78%
ALPINE ASSOCIATES MANAGEMENT INC. 534,180$63,092,0002.58%
Pentwater Capital Management LP 1,178,000$139,134,0001.68%
Temasek Holdings (Private) Ltd 1,240,000$146,456,0000.63%
AQR Arbitrage LLC 142,733$16,858,0000.59%
FORT, L.P. 9,761$1,153,0000.34%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders